Praetorian Wealth Management Inc. Invests $291,000 in Johnson & Johnson (NYSE:JNJ)

Praetorian Wealth Management Inc. purchased a new position in Johnson & Johnson (NYSE:JNJFree Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,857 shares of the company’s stock, valued at approximately $291,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Hibernia Wealth Partners LLC bought a new position in Johnson & Johnson in the third quarter worth approximately $27,000. FNY Investment Advisers LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $37,000. Tower View Wealth Management LLC grew its stake in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares during the last quarter. Creative Capital Management Investments LLC grew its stake in Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $48,000. 68.40% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on JNJ. Morgan Stanley dropped their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 13th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $177.31.

View Our Latest Analysis on Johnson & Johnson

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $155.76 on Thursday. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The stock has a 50 day moving average of $159.37 and a two-hundred day moving average of $156.84. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market cap of $375.35 billion, a P/E ratio of 11.28, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. During the same period in the previous year, the business earned $2.35 EPS. Johnson & Johnson’s quarterly revenue was down 9.7% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were paid a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.